Namita Thapar's Investment Grows 38,200% As Emcure Pharma Lists At 31% Premium On NSE

Namita Thapar is likely laughing all the way to the bank as the Emcure Pharmaceuticals executive director’s current investment in the company grew to ₹671 crore following a 31% listing premium on the NSE.

What Happened: Emcure Pharmaceuticals got listed on the NSE at ₹1,325.05, a premium of 31.45% over its issue price of ₹1,008. The pharma firm’s ₹1,952.03 crore IPO saw significant investor interest, being subscribed 67.87 times.

The retail book was subscribed seven times while the non-institutional investor (NII) portion was subscribed 48 times. The qualified institutional buyers (QIBs) portion was subscribed 195 times.

See Also: HDFC Bank Shares Under Pressure As Brokerage Downgrades Stock, Cuts Target

The Shark Tank India investor had bought 63.39 lakh shares in the company at an average price of ₹3.46, putting ₹2.19 crore in the company. Thapar had put up 12.68 lakh shares in the offer-for-sale component of the IPO. With the success of the IPO, she would have made around ₹127.87 crore from her share sale.

Her current investment would have grown to ₹671 crore, with her remaining 50.71 lakh shares giving her a bumper return. On a per-share basis, the initial investment would give her a return of around 38,200%, based on the listing price.

The IPO consisted of a fresh issue of 0.79 crore shares aggregating to ₹800 crore and an offer for sale of 1.14 crore shares aggregating to ₹1,152.03 crore. The issue had a price band of ₹960 to ₹1,008 per share.

Before the IPO, Emcure had raised ₹582.6 crores from anchor investors consisting of Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley.

Read Next: Zerodha Refunds ₹9 Lakh To Trader Who Blames Bug For Missing Out On Profits

Don't miss a beat on the share market. Get real-time updates on top stock movers and trading ideas on Benzinga India Telegram channel.

Posted In: EquitiesNewsFinancingIPOsMarketsMediaEmcure PharmaceuticalsNamita Thapar